Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
Emperor Qinshihuang museum launches online ticket platform for overseas touristsScaling the heights of beautyChangsha captures hearts of HK touristsXi Meets with Mongolian PMXi Story: Spirit of Ancient Poet Resonates in Modern ChinaOver 600 enterprises sign up for 7th CIIEGeopark listed in UNESCO networkGeopark listed in UNESCO networkShenzhen has a taste of France at food expoQiaopi, Letters of Love from Overseas Chinese
0.1376s , 6499.546875 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,Global Gleam news portal